AIxCrypto Holdings, Inc. (NASDAQ: AIXC)

Qualigen Therapeutics, Inc., often recognized by its ticker symbol QLGN, operates within the biotechnology industry, specifically focused on developing treatments for adult and pediatric cancer. The company's main business activities revolve around two primary therapeutic programs: QN-302, an early-clinical-stage investigational treatment, and Pan-RAS, a preclinical therapeutic program. These programs are primarily based in the United States, with clinical trials taking place in Grand Rapids, Michigan, and Scottsdale, Arizona.

Qualigen Therapeutics generates revenue through the development and potential licensing of its therapeutic programs. QN-302 is a small molecule G-quadruplex (G4)-selective transcription inhibitor, designed with a strong binding affinity to G4s prevalent in cancer cells. This drug is currently undergoing a Phase 1a clinical trial and holds the potential to demonstrate superior efficacy against pancreatic ductal adenocarcinoma (PDAC), which represents 98% of pancreatic cancers. Pan-RAS, on the other hand, is a family of pan-RAS inhibitor small molecule drug candidates that work by blocking RAS mutations directly, thereby inhibiting tumor formation, especially in pancreatic, colorectal, and lung cancers.

Within the biotechnology industry, Qualigen Therapeutics competes with various other companies also focused on cancer treatments. The company's competitive advantage lies in its unique therapeutic approaches, such as the G4-selective transcription inhibition of QN-302 and the pan-RAS inhibition of Pan-RAS. These approaches differentiate Qualigen Therapeutics from its competitors, providing a unique selling proposition.

Unfortunately, the provided text does not mention any specific names of customers for Qualigen Therapeutics. However, it is mentioned that the company has obtained FDA clearance/approval for its QN-302 Phase 1a clinical trial, indicating that the FDA is one of its key stakeholders.

In terms of brand names and trade names, Qualigen Therapeutics has QN-302 and Pan-RAS in its product pipeline. These names represent the company's primary focus and its potential future revenue streams. While the company does not have any directly-owned issued patents and pending patent applications, it does hold an exclusive worldwide in-license agreement with the University of Louisville's Research Foundation for the intellectual property covering the RAS family of pan-RAS inhibitor small molecule drug candidates. This agreement further strengthens the company's position in the industry.